A reduced dose of radiotherapy and chemotherapeutic agents and an extended application of the monoclonal Epidermal Growth Factor Receptor (EGFR) antagonist cetuximab with a lower potential of adverse events might improve the quality of life of these cancer patients without the risk of an early recurrence. The gene discussed is EGFR; the disease is cancer.